SCHEMBL16028183

SCHEMBL16028183

CCn1cc(-c2cc(Oc3ccc(NC(=O)NC(=O)C(C)(C)C)nc3C)ccn2)cn1

nearest known ligand 0.80

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 20/20 0.80
▸ PDGFRA P16234 17/20 0.80
▸ PDGFRB P09619 12/20 0.80
▸ CYP2C9 P11712 1/20 0.80
▸ FLT3 P36888 4/20 0.69
▸ MET P08581 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16028203 0.89 CSF1R (1.00) CSF1RPDGFRAPDGFRBCYP2C9FLT3
SCHEMBL16029319 0.89 CSF1R (0.80) CSF1RPDGFRAPDGFRBCYP2C9FLT3
SCHEMBL16028117 0.87 CSF1R (0.89) CSF1RPDGFRAPDGFRBCYP2C9FLT3
SCHEMBL16028666 0.85 CSF1R (0.85) CSF1RPDGFRAPDGFRBCYP2C9FLT3
SCHEMBL16028547 0.84 CSF1R (0.85) CSF1RPDGFRAPDGFRBCYP2C9FLT3
SCHEMBL16028918 0.83 CSF1R (1.00) CSF1RPDGFRAPDGFRBCYP2C9FLT3
SCHEMBL16029019 0.83 CSF1R (0.84) CSF1RPDGFRAPDGFRBCYP2C9FLT3
SCHEMBL16028028 0.83 CSF1R (0.85) CSF1RPDGFRAPDGFRBCYP2C9FLT3
SCHEMBL16028269 0.82 CSF1R (1.00) CSF1RPDGFRAPDGFRBCYP2C9FLT3
SCHEMBL16028661 0.81 CSF1R (0.85) CSF1RPDGFRAPDGFRBCYP2C9FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2968287-B1 N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS LLC (US) 2020-06-24 — — EP claimed
US-9382228-B2 N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2016-07-05 — — US claimed
EP-2968287-A2 N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES Deciphera Pharmaceuticals, LLC (US) 2016-01-20 — — EP claimed
US-20140275080-A1 N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities DECIPHERA PHARMACEUTICALS, LLC (US) 2014-09-18 — — US claimed
WO-2014145028-A2 N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2014-09-18 — — WO claimed
CN-112047927-A N-acyl-N' - (pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activity 德西费拉制药有限责任公司 2020-12-08 — — CN disclosed
CN-105228620-B N-acyl-N' - (pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activity 德西费拉制药有限责任公司 2020-09-04 — — CN disclosed
EP-2968287-B1 N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS LLC (US) 2020-06-24 — — EP disclosed
EP-2968287-B1 N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS LLC (US) 2020-06-24 — — EP disclosed
CN-110563700-A N-acyl-N' - (pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activity 德西费拉制药有限责任公司 2019-12-13 — — CN disclosed
US-9382228-B2 N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2016-07-05 — — US disclosed
US-9382228-B2 N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2016-07-05 — — US disclosed
US-9382228-B2 N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2016-07-05 — — US disclosed
EP-2968287-A2 N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES Deciphera Pharmaceuticals, LLC (US) 2016-01-20 — — EP disclosed
US-20140275080-A1 N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities DECIPHERA PHARMACEUTICALS, LLC (US) 2014-09-18 — — US disclosed
US-20140275080-A1 N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities DECIPHERA PHARMACEUTICALS, LLC (US) 2014-09-18 — — US disclosed
US-20140275080-A1 N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities DECIPHERA PHARMACEUTICALS, LLC (US) 2014-09-18 — — US disclosed
WO-2014145028-A2 N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2014-09-18 — — WO disclosed
WO-2014145028-A2 N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2014-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275080-A1 N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities KIT, CSF1R, CSF3R CSF1R 2/4885PDGFRA 5/4885PDGFRB 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback